Table 2.
Univariate and multivariate cox regression analysis of post recurrence survival in gastric cancer with late recurrence.
| Variables | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | |
| Sex (female vs male) | 0.90 (0.45–1.80) | 0.760 | ||
| Age (yr) | 1.01 (0.97–1.05) | .709 | ||
| FOBT (positive vs negative)† | 0.99 (0.50–1.99) | 0.992 | ||
| BMI† (kg/m2) | 0.94 (0.88–1.02) | 0.126 | ||
| HB† (g/L) | 1.00 (0.99–1.01) | .815 | ||
| RBC† (×10^12/L) | 0.99 (0.61–1.62) | .964 | ||
| TP† (g/L) | 0.98 (0.93–1.03) | .405 | ||
| ALB† (g/L) | 0.96 (0.89–1.04) | .340 | ||
| GLB† (g/L) | 0.97 (0.88–1.07) | .612 | ||
| A/G† | 1.01 (0.15–6.89) | .992 | ||
| NEUT† (×10^9/L) | 0.89 (0.73–1.08) | .241 | ||
| LY† (×10^9/L) | 1.13 (0.70–1.84) | .615 | ||
| MONO† (×10^9/L) | 0.41 (0.02–7.46) | 0.548 | ||
| CRP† (mg/L) | 0.96 (0.91–1.02) | .201 | ||
| PLT† (×10^9/L) | 1.00 (1.00–1.01) | .702 | ||
| NLR† | 0.88 (0.72–1.10) | .254 | ||
| LCR† | 0.97 (0.90–1.05) | .406 | ||
| PLR† | 1.00 (1.00–1.00) | .894 | ||
| LMR† | 1.16 (0.91–1.49) | .231 | ||
| FOBT (Positive vs Negative)‡ | 2.37 (1.15–4.90) | .020* | ||
| BMI‡ (kg/m2) | 0.88 (0.75–1.04) | 0.127 | ||
| HB‡ (g/L) | 0.98 (0.96–0.99) | .038* | 0.97 (0.96–0.99) | .008* |
| RBC‡ (×10^12/L) | 0.72 (0.38–1.37) | 0.317 | ||
| TP‡ (g/L) | 0.92 (0.87–0.97) | .001* | ||
| ALB‡ (g/L) | 0.91 (0.85–0.97) | .002* | ||
| GLB‡ (g/L) | 0.94 (0.86–1.04) | 0.226 | ||
| A/G‡ | 0.38 (0.11–1.39) | .145 | ||
| NEUT‡ (×10^9/L) | 1.20 (1.04–1.38) | 0.012* | ||
| LY‡ (×10^9/L) | 0.67 (0.31––1.46) | .317 | ||
| MONO‡ (×10^9/L) | 0.81 (0.11–5.79) | .837 | ||
| CRP‡ (mg/L) | 1.01 (0.99–1.02) | .199 | ||
| PLT‡ (×10^9/L) | 1.00 (1.00–1.00) | 0.964 | ||
| NLR‡ | 1.07 (1.02–1.13) | 0.009* | 1.06 (1.00–1.12) | .045* |
| LCR‡ | 0.83 (0.68–1.00) | 0.057 | ||
| PLR‡ | 1.00 (1.00–1.00) | 0.059 | ||
| LMR‡ | 1.04 (0.83–1.30) | .757 | ||
| Reference pattern | ||||
| Local | Reference | |||
| Abdominal | 1.17 (0.34–4.10) | 0.801 | ||
| Distant | 0.92 (0.27–3.14) | .892 | ||
| Multiple | 0.90 (0.15–5.39) | .907 | ||
| Positive lymph node ratio | 3.97 (0.93–16.93) | .062 | ||
| Differentiation | ||||
| Well | Reference | |||
| Moderate Poor |
0.80 (0.08–7.74) 3.33 (0.45–24.52) |
.850 .238 |
||
| Tumor size (cm) | 1.08 (0.95–1.23) | .232 | ||
| Resection range (subtotal vs total) | 0.62 (0.32–1.20) | 0.150 | ||
| Surgical method | ||||
| Billroth I | Reference | |||
| Billroth II | 0.84 (0.30–2.32) | .736 | ||
| Roux-en-Y | 1.28 (0.47–3.51) | .627 | ||
| Surgical procedure (LS vs OS) | 0.81 (0.42-1.57) | .536 | ||
| Tumor location | ||||
| High | Reference | |||
| Middle | 0.74 (0.26–2.09) | 0.573 | ||
| Low | 0.93 (0.34-2.54) | 0.881 | ||
| Borrmann classification | ||||
| I | Reference | |||
| II | 3.48 (0.39–31.35) | .266 | ||
| III | 3.07 (0.41–22.78) | 0.272 | ||
| IV | 4.17 (0.48–36.04) | 0.194 | ||
| pTNM (III vs II) | 1.83 (0.88–3.77) | .104 | ||
| Postoperative chemotherapy (yes vs no) | 1.67 (0.51–5.46) | 0.400 | ||
| Clavein Dindo classification | ||||
| I | Reference | |||
| II | 0.76 (0.37–1.55) | 0.450 | ||
| III | 0.53 (0.07–3.92) | .533 | ||
A/G = albumin-globulin ratio, ALB = albumin, BMI = body mass index, CI = confidential intervals, CRP = C-reactive protein, FOBT = fecal occult blood test, GLB = globulin, HB = hemoglobin, HR = hazard ratio, LCR = lymphocyte-C-reactive protein ratio, LMR = lymphocyte-monocyte ratio, LS = laparoscopic surgery, LY = Lymphocyte, MONO = monocyte, NEUT = neutrophil, NLR = neutrophil–lymphocyte ratio, OS = open surgery, PLR = platelet-lymphocyte ratio, PLT = platelet, RBC = red blood cell, TNM = tumor, node, metastasis, TP = total protein.
*
P < .05.
†
Preoperative variables.
‡
Variables at the time of recurrence.